Clinical Trial Update: Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial is planned to evaluate the use of allogeneic natural killer (NK) cells in high-risk advanced stage III-IV nasopharyngeal carcin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Allogeneic NK cells (allogeneic natural killer cells)

Snippet

Sponsor: Singapore General Hospital | Conditions: Nasopharyngeal Carcinoma (NPC), Minimal Residual Disease | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING